Drug Information

Drug General Information
Drug ID
D0C6MS
Former ID
DND000083
Drug Name
PF-04991532
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Phase 2 [523436]
Company
Pfizer
Target and Pathway
Target(s) Glucokinase Target Info Activator [532788], [533022]
KEGG Pathway Glycolysis / Gluconeogenesis
Galactose metabolism
Starch and sucrose metabolism
Amino sugar and nucleotide sugar metabolism
Butirosin and neomycin biosynthesis
Metabolic pathways
Biosynthesis of antibiotics
Carbon metabolism
Insulin signaling pathway
Insulin secretion
Prolactin signaling pathway
Glucagon signaling pathway
Type II diabetes mellitus
Maturity onset diabetes of the young
Central carbon metabolism in cancer
Pathway Interaction Database FOXA2 and FOXA3 transcription factor networks
HIF-1-alpha transcription factor network
PathWhiz Pathway Nucleotide Sugars Metabolism
Starch and Sucrose Metabolism
Galactose Metabolism
Trehalose Degradation
Reactome Regulation of gene expression in beta cells
Glucose transport
Glycolysis
WikiPathways SIDS Susceptibility Pathways
Glycolysis and Gluconeogenesis
MAPK Signaling Pathway
Regulation of beta-cell development
Metabolism of carbohydrates
Hexose transport
References
Ref 523436ClinicalTrials.gov (NCT01338870) Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes. U.S. National Institutes of Health.
Ref 532788The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139.
Ref 533022Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment. Drug Metab Dispos. 2015 Feb;43(2):190-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.